Close menu




December 1st, 2020 | 10:23 CET

BP, Triumph Gold, K+S - who offers the best trading opportunities?

  • Investments
Photo credits: pixabay.com

The asset class "commodities" offers investors a broad and exciting investment universe. Especially the high cyclicality of commodity prices provides opportunities. When Gold & Co is in fashion, stocks that operate in this field often develop explosively. But also, commodities that are not among the favorites of investors at times, or are subject to strong fluctuations, such as oil & gas or potash, offer good (countercyclical) investment and trading opportunities.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: CA8968121043 , GB0007980591 , DE000KSAG888

Table of contents:


    BP PLC - 30% price increase in the last weeks, use volatility for trading

    The price of oil has gone off the rails this year. The supply and demand situation is difficult to assess given the fear of recession and the power games of significant players. The volatility was partly absurd.

    It is therefore hardly surprising that large oil companies are among the worst money destroyers in 2020. The share price charts were correspondingly positive. In recent weeks, however, the sentiment of the oil industry has also improved in the course of the generally good stock market phase. The BP share gained 30% last month. The payment of a dividend and even the continued adherence to payouts may seem like a marginal note, but it is not, given the disastrous figures. All because BP is demonstrating financial strength and sending a clear signal that it can successfully adapt structures and costs through a transformation process.

    In the first nine months of the financial year, the industry heavyweight posted a loss of no less than USD 21.7 billion, compared with a profit of USD 4 billion a year earlier. But the worst is probably behind the shareholders because the terrible loss stems mainly from Q2. The third quarter was "only" in the red with USD 450 million. Nevertheless, it may be too early to give the all-clear. For the disagreement within the oil network, Opec+ over an extension of production cuts is causing dark clouds to gather again. No reason for bad mood though - volatile stock market phases are full of trading opportunities.

    TRIUMPH GOLD CORP - bet on the further rise of gold and copper

    Gold is the best-known crisis currency. We have seen this impressively in recent months. Even though the price of the precious metal has recently fallen, experts agree that the price can only rise in the medium term. For a completely different reason, the industrial metal, copper, has developed strongly this year. The forecast demand in the wake of electromobility suggests that the gap between supply and demand will diverge significantly in the future. It is certainly not a bad idea to position oneself in the two raw materials.

    With shares in Triumph Gold, investors can do just that. Triumph Gold Corp is a mineral exploration Company currently focused on its 100% owned Freegold Mountain project in the Yukon. The property is located in the gold-copper belt of the Dawson Range, where the Casino copper deposit, the Coffee gold deposit and the Klaza gold prospect, are also located.

    The Vancouver-based Company currently has a market capitalization of CAD 25 million. The stock has lost approximately 50% over the summer and now offers an attractive level for (post) purchases.

    K+S AG - Commerzbank sees further price potential of 30%

    In recent weeks, the price of the K+S share has experienced a rollercoaster ride. After a long dry spell, the share finally appeared to be heading for liberation in mid-October with the announcement that it intended to sell its salt business in North and South America. However, the share price quickly retreated from the price level of over EUR 7 and corrected to EUR 5.66.

    Today, the share is 2 euros higher again. What are the reasons? Several analysts have now issued price targets of over EUR 7. Commerzbank stood out particularly positively last Friday. The Coba analyst upgraded K+S from "hold" to "buy" and increased the target price from EUR 7 to EUR 10! The expert cited as reasons, the unexpectedly high proceeds expected from the sale of the American salt business, a significant reduction in balance sheet risks after write-downs, and a positive outlook.

    As already mentioned, volatility offers trading opportunities.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read